Isospec Analytics Raises $1.9 Million in Pre-Seed Funding to Revolutionize Disease Detection

Funding Announcement

At Isospec Analytics, a Swiss-based startup emerging from EPFL, we are proud to announce the successful closure of a $1.9 million pre-seed funding round. This significant investment will accelerate the development and commercialization of our groundbreaking biomolecular analysis technology.

Our Technology

At Isospec Analytics, we've developed a revolutionary approach to analyzing small biological molecules in blood samples. Our technology can identify up to 15,000 unique molecules - a dramatic improvement over current methods that recognize less than 5% of these crucial biomarkers.

Key features of our technology include:

‍

• Rapid analysis: Results in hours instead of weeks or months
• Comprehensive identification: Up to 15,000 molecules per sample
• Multidisciplinary approach: Combining analytical chemistry, photonics, and cryogenic materials

Impact on Healthcare

Our innovative technology has the potential to transform healthcare in several ways:

‍

1. Earlier Disease Detection: By identifying a broader range of biomarkers, we can potentially diagnose diseases at much earlier stages.
2. Personalized Medicine: Comprehensive molecular profiles could lead to more tailored treatment plans.
3. Accelerated Drug Development: Insights into disease mechanisms at the molecular level can speed up the creation of new treatments.

Current Progress

• Operational lab providing molecular identification services
• Serving customers across Europe, the US, and Japan
• Collaborations with hospitals and research institutes for diagnostic test development

Future Plans

With this funding, we aim to:

‍

1. Invest in automation technologies
2. Expand our software engineering capabilities
3. Increase testing capacity and speed
4. Develop standalone diagnostic tests (pending regulatory approvals)

About the Founders

Isospec Analytics was founded by Thomas Rizzo, Ahmed Ben Faleh, and Stephan Warnke, who met at EPFL seven years ago. Their combined expertise in various scientific disciplines has been crucial in developing this innovative technology.

Investor Support

This funding round was led by Founderful, with additional participation from Tiny.vc, another.vc, and Venture Kick. Alex Stöckl, a partner at Founderful, has joined our board, bringing valuable expertise to guide our growth.

‍

‍